Clinical Trials Browser

Terminated × Tiragolumab × Plasma cell × Clear all

NCT04045028 2023-04-07

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Terminated

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphoma, B-Cell